Nouscom: Made official
She was already serving as interim CEO since Nouscom founder Alfredo Nicosia retired in May 2019. Now, Marina Udiers appointment at the Basel-based immuno-oncology company has been made permanent.
ADVERTISEMENT
About Michael Kuhrt
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Entries by Michael Kuhrt
TrakCel: New at the helm
Co-founder Fiona Withey is the new Chief Executive Officer of TrakCel, a software developer of orchestration systems for advanced therapies. Co-founder Ravi Nalliah was appointed to the role of Chief Strategy Officer.
Applied Photophysics: Permanent head
Applied Photophysics Limited, active in biophysical characterization of biomolecules, has appointed Tim Flanagan as Chief Executive Officer and member of the Board of Directors.
Centrient Pharmaceuticals: New CEO
Ex-Sandoz Head of Global Franchises Rex Clements is taking over as CEO of Centrient Pharmaceuticals. Erstwhile Centrient CEO Karl Rotthier has decided to step down, the company said.
Sofinnova: Industrial biotech promotion
European venture capital firm Sofinnova Partners announced the promotion of Michael Krel to Partner of the Industrial Biotechnology team. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.
Ipsen: New VP and CMO incoming
Ipsen has named steven Hildemann as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance, effective March 2020.
Wellington Partners: Sideways move
Karl Naegler, who has been a partner at the investment company Gimv since 2011, has joined the competition. He is now Managing Partner at leading European venture capital firm Wellington Partners.
Zelluna: Scientist turns CEO
Norwegian biopharma company Zelluna Immunotherapy appointed erstwhile CSO Namir Hassan as Chief Executive Officer.
Creoptix: New woman at the helm
Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, has named Line Stigen Raquet as Chief Executive Officer.
Is your reality quite different from other people’s reality?
While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish a completely new model for how to spur innovation. Eliminating intellectual property-related restrictions, open biology promises rapid and local production of biomaterials, diagnostics, or genome-edited crops in countries with no established IP system.